New Faces of Immunotherapy

New Faces of Immunotherapy

07 March 2016,   By ,   0 Comments

Immunotherapy is changing cancer as we know it. Experts predict that in just 10 years, immunotherapy will form the backbone for over 60% of cancer treatments, as opposed to less than 3% today.

As the cancer treatment landscape shifts from traditional to immune-targeted therapies, it’s important to understand the benefits and limitations of each approach. By examining the faces of immunotherapy, we can best understand how immunotherapy is changing the world.

The Old

  • Surgery
    Surgery can be used to completely remove or debulk a tumor.
  • Chemotherapy
    Chemotherapeutics are designed to kill fast-growing cells. These drugs can kill cancer cells but also kill or slow the growth of healthy cells.
  • Radiation
    Radiation therapy uses high doses of radiation to kill or slow the growth of cancer cells.

The New

  • Monoclonal Antibodies
    These drugs are designed to bind specific targets in the body.
  • Cancer Vaccines
    Vaccines expose the immune system to specific ‘antigens’. This triggers the immune system to recognize and destroy a specific target material.
  • Cell Therapies
    Cell-based immunotherapies aim to generate highly specific T cells that can recognize and eliminate cancer throughout the body.

Taking the Fight Directly to the Tumor

Intratumoral immunotherapies are administered directly to the tumor. One such approach is OncoSec’s ImmunoPulse® platform, which delivers DNA directly into tumor cells. This process is designed to stimulate the immune system to recognize and kill cancer cells. Their investigational therapy, ImmunoPulse® IL-12, harnesses the power of IL-12, a naturally occurring protein with immune-stimulating functions.

  • Over 70 patients treated to-date in multiple tumor types, including melanoma, breast cancer, head & neck cancer, and Merkel cell carcinoma
  • Positive clinical response and favorable safety profile observed across multiple trials
  • Data suggest ImmunoPulseTM IL-12 can generate an anti-cancer immune response and enhance response to other therapies

Real Time Web Analytics